Last reviewed · How we verify
BI-1206 single agent expansion phase
BI-1206 single agent expansion phase is a Biologic drug developed by Cancer Research UK. It is currently in Phase 1 development.
At a glance
| Generic name | BI-1206 single agent expansion phase |
|---|---|
| Sponsor | Cancer Research UK |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BI-1206 single agent expansion phase CI brief — competitive landscape report
- BI-1206 single agent expansion phase updates RSS · CI watch RSS
- Cancer Research UK portfolio CI
Frequently asked questions about BI-1206 single agent expansion phase
What is BI-1206 single agent expansion phase?
BI-1206 single agent expansion phase is a Biologic drug developed by Cancer Research UK.
Who makes BI-1206 single agent expansion phase?
BI-1206 single agent expansion phase is developed by Cancer Research UK (see full Cancer Research UK pipeline at /company/cancer-research-uk).
What development phase is BI-1206 single agent expansion phase in?
BI-1206 single agent expansion phase is in Phase 1.